Haemonetics Corp. 10-Q Summary: Quarter Ended July 3, 1999
Business Context and Reporting Period
Haemonetics Corporation designs, manufactures, and markets automated blood processing systems, including blood bank, surgical, and plasma products. This report covers the first quarter of fiscal year 2000, ended July 3, 1999 (13 weeks). The prior comparable period (ended July 4, 1998) included 14 weeks due to a 53-week fiscal year.
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 | Change |
|---|---|---|---|
| Net Revenues | $69.1 million | $72.0 million | (4.0%) |
| Gross Profit | $32.8 million | $36.0 million | (8.8%) |
| Gross Margin | 47.5% | 50.0% | (2.5 pts) |
| Operating Income | $8.5 million | $7.3 million | 15.7% |
| Operating Margin | 12.2% | 10.1% | +2.1 pts |
| Net Income | $6.0 million | $4.9 million | 21.9% |
| Diluted EPS | $0.223 | $0.184 | 21.2% |
| Cash from Operations | $7.1 million | $10.9 million | (34.8%) |
| Net Debt | $8.1 million | $2.9 million | +185% |
| Working Capital | $157.5 million | $162.2 million | (2.9%) |
Material Changes vs. Prior Period
- Revenue: Reported revenues declined 4.0% primarily due to unfavorable foreign currency fluctuations. On a constant currency and comparable basis (adjusting for the extra week in 1998), revenues increased 7.9%.
- Product Mix: Disposable sales decreased 3.6% at actual rates but increased 8.7% on a constant currency basis. Equipment revenues grew 19.1% (27.2% constant currency), driven by sales in Asia.
- Profitability: Operating income increased 15.7% despite lower gross profit dollars, driven by a 16.6% reduction in Selling, General, and Administrative (SG&A) expenses. The tax provision rate decreased to 32.0% from 35.0%.
- Discontinued Operations: The company completed the divestiture of its Blood Bank Management Services (BBMS) business in May 1999. Consequently, BBMS operating losses were minimal in Q1 1999 compared to Q1 1998.
- Liquidity: Net debt increased by $5.4 million due to higher capital expenditures ($6.9 million) and the repurchase of 521,337 shares of treasury stock for $9.6 million.
Guidance, Outlook, and Risks
- Tax Outlook: Management expects the effective tax rate to remain at 32.0% for the full fiscal year 2000.
- Year 2000 (Y2K) Compliance: The company estimates total Y2K remediation costs between $2.5 million and $3.3 million, with approximately 85% already spent. While internal systems are largely compliant, risks remain regarding third-party vendor readiness and potential supply chain disruptions.
- Euro Conversion: The company is preparing for the Euro adoption in 11 EU countries, with a target system conversion date of April 2, 2001. Management does not anticipate a material financial impact.
- Market Risks: Significant exposure to foreign exchange rates (over two-thirds of revenue is international) and interest rate fluctuations on fixed-rate debt.
Investor Verification Checklist
- Verify the sustainability of the 8.7% constant currency revenue growth across all three product lines (Surgical, Blood Bank, Plasma).
- Confirm the status of critical vendor Y2K compliance to assess supply chain risk.
- Monitor the impact of the strong U.S. dollar on future reported revenues versus constant currency performance.
- Review the adequacy of the $2.9 million remaining Y2K budget and potential for cost overruns.
- Assess the long-term impact of the completed BBMS divestiture on future operating leverage.